Michael Schenker - Concepedia

Author

Michael Schenker

Bristol-Myers Squibb (United States)ORCID

Also Known As

Cristina Marinela Oprean, M Schenker, M. Schenker, MICHAEL SCHENKER, Michael Schenker, R Mccosh, Schenker, M.

240

Publications

17.2K

Citations

H-Index

105

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Institute of Oncology Prof. Dr. Ion Chiricuta University of Medicine and Pharmacy of Craiova Hospital Universitario 12 De Octubre National and Kapodistrian University of Athens

About

Michael Schenker is an author at Bristol-Myers Squibb (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	47	6.6K
2	Health Sciences	13	14	540
3	Nursing	1	1	12
4	Public Health	1	1	14
5	Social Sciences	1	1	12

Michael Schenker

Publications

16.8K

Citations

H-Index

Page 1

	Year	Citations
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial Yelena Y. Janjigian, Kohei Shitara, Markus Moehler, The Lancet Chemotherapy Versus ChemotherapyEsophageal CancerGastrointestinal OncologyMedicineCheckmate 649	2021	2.7K
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, New England Journal of Medicine	2017	2.1K
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer Ronan J. Kelly, Jaffer A. Ajani, Thomas Zander, New England Journal of Medicine	2021	1.6K
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial Luis Paz‐Ares, Tudor–Eliade Ciuleanu, Manuel Cobo, The Lancet Oncology Non-small-cell Lung CancerMedicinePharmacologyImmune Checkpoint InhibitorPharmacotherapy	2021	1.3K
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma Dean F. Bajorin, J. Alfred Witjes, Jürgen E. Gschwend, New England Journal of Medicine	2021	968
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer David Miles, Joseph Gligorov, Fabrice André, Annals of Oncology	2021	689
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, The Lancet Oncology Checkmate 238Surgical OncologyMedicineMelanomaPathology	2020	505
Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 Yu Jeong Bang, Eduardo Yañez Ruiz, Eric Van Cutsem, Annals of Oncology	2018	495
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles, New England Journal of Medicine	2023	421
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer Kohei Shitara, Jaffer A. Ajani, Markus Moehler, Nature	2022	415

Page 1